Sign in
Taking people in United StatesPhase 2

Etrasimod for Teens With Moderate to Severe Ulcerative Colitis

Tests etrasimod in adolescents aged 12 to 17 with ulcerative colitis.

Key facts

Who runs it
Pfizer
Where
Abilene, Boston, Chicago, Cleveland, Fort Worth, Garden Grove, Little Rock, Loma Linda, Orlando, Royal Oak, San Bernardino, and San Francisco, United StatesSee the 21 sitesAlso in 6 other countries, 29 sites
Registry title
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Status
Recruiting
Phase
Phase 2
People taking part
36 people, planned
Started
16 Dec 2022
Expected to end
10 Jul 2033
Type of study
Interventional
Treatments tested
  • Etrasimod
Record updated
27 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for teenagers with moderately to severely active ulcerative colitis. All take etrasimod.

Age
12 to 17 years
Sex
All sexes
Disease stage
Ulcerative colitis that is moderately to severely active
Earlier treatment
People can join while taking a therapeutic dose of select ulcerative colitis treatments.

Main reasons for not taking part

  • Severe extensive colitis
  • Crohn's disease or indeterminate colitis, or a fistula linked to Crohn's disease
  • Microscopic colitis, ischemic colitis, or infectious colitis

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Have a diagnosis of ulcerative colitis (UC) that is moderately to severely active
  • Participants are permitted to be receiving a therapeutic dose of select UC therapies

Who cannot take part

  • Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD
  • Severe extensive colitis
  • Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 12 and 17 years old?

Where in United States

Also in 6 other countries, 29 sites

  • ACT-Midwest G1Abilene, United StatesTaking people
  • Boston Children's HospitalBoston, United StatesTaking people
  • University of Chicago Medical CenterChicago, United StatesTaking people
  • University Hospitals Cleveland Medical Center Rainbow Babies & Children's HospitalCleveland, United StatesTaking people
  • University Hospitals Cleveland Medical Center*Cleveland, United StatesTaking people
  • Cook Children's Health Care System-Dodson Specialty ClinicsFort Worth, United StatesTaking people
  • Cook Children's Medical CenterFort Worth, United StatesTaking people
  • Valley View Wellness Medical CenterGarden Grove, United StatesTaking people
  • Arkansas Children'sLittle Rock, United StatesNot yet recruiting
  • Arkansas Children's (IP Address)Little Rock, United StatesNot yet recruiting
  • Loma Linda Children's HospitalLoma Linda, United StatesNot yet recruiting
  • Loma Linda University Clinical Trial CenterLoma Linda, United StatesNot yet recruiting
  • Loma Linda University Eye InstituteLoma Linda, United StatesNot yet recruiting
  • Loma Linda University Medical CenterLoma Linda, United StatesNot yet recruiting
  • Loma Linda University Pediatric ClinicsLoma Linda, United StatesNot yet recruiting
  • Arnold Palmer Hospital - Center for Digestive Health and NutritionOrlando, United StatesTaking people
  • William Beaumont Hospital/Corewell Health - EastRoyal Oak, United StatesTaking people
  • William Beaumont Hospitals Reference LaboratoryRoyal Oak, United StatesTaking people
  • Loma Linda University Children's Hospital Pediatric Specialty ClinicsSan Bernardino, United StatesNot yet recruiting
  • University of California San FranciscoSan Francisco, United StatesTaking people
  • University of California,San Francisco Pediatric ClinicalResearch Center (PCRC)San Francisco, United StatesTaking people

About the trial

What the trial wants to find out

The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to < 18 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).

The group in the trial

  • EtrasimodTreatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Plain-language title
Etrasimod for Teens With Moderate to Severe Ulcerative ColitisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05287126, who can take part
Record updated
27 October 2026